Phase IIb, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture
Latest Information Update: 30 May 2024
At a glance
- Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
- Indications Fracture
- Focus Proof of concept; Therapeutic Use
- Acronyms ALLOB-TF2
- Sponsors BioSenic
- 30 May 2024 This trial has been Discontinued in Poland, according to European Clinical Trials Database record.
- 15 May 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 12 May 2024 This trial has been Prematurely Ended in Czechia and Germany (2024-04-30) according to Eudra record.